Want to see OLMA full AI Analyst Report?
OLMA Stock Chart & Stats
$11.70
-$0.04(-0.34%)
At close: 4:00 PM EDT
$11.70
-$0.04(-0.34%)
Day’s Range― - ―
52-Week Range$5.36 - $36.26
Previous CloseN/A
Volume806.83K
Average Volume (3M)1.59M
Market Cap
$935.35M
Enterprise Value$849.31
Total Cash (Recent Filing)$461.07M
Total Debt (Recent Filing)$660.00K
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Nov 10, 2026EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.12
Shares Outstanding87,497,604
10 Day Avg. Volume930,349
30 Day Avg. Volume1,592,633
Financial Highlights & Ratios
PEG Ratio0.89
Price to Book (P/B)4.55
Price to Sales (P/S)0.00
P/FCF Ratio-14.83
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$38.13Price Target Upside225.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.38
Revenue Forecast (FY)$2.25M
Bulls Say, Bears Say
Bulls Say
Very Low Leverage And Balance-sheet FlexibilityMinimal debt gives Olema financial flexibility while it funds clinical development. The $486.6M asset base provides support for ongoing operations, although continued losses could reduce this cushion over time.
Late-stage Lead Program With Broader Oncology PipelineTwo Phase 3 palazestrant trials create a potential path toward commercial validation in ER-positive breast cancer. The additional OP-3136 program broadens the pipeline and reduces reliance on a single clinical asset.
Strategic Bayer Collaboration Expands OP-3136 PotentialThe Bayer collaboration extends OP-3136 into prostate cancer and provides access to a complementary therapy without surrendering global commercial rights. Joint development may help generate broader validation for the KAT6 program.
Bears Say
No Product Revenue Or Commercial TractionOlema remains entirely dependent on clinical success because it has no approved products or recurring commercial revenue. This leaves the company without an operating revenue base to absorb research, development, and corporate expenses.
Widening Losses And Sustained Cash BurnLarge recurring cash outflows indicate that development spending is not self-funded and will remain a central financial risk. Rising losses increase the amount of capital required before any candidate can generate revenue.
Dependence On External FinancingWithout product sales, Olema must rely on equity issuance or other financing to sustain clinical programs. Continued capital needs can dilute existing shareholders and may constrain development choices if funding conditions become less favorable.
Olema Pharmaceuticals News
OLMA FAQ
What was Olema Pharmaceuticals, Inc.’s price range in the past 12 months?
Olema Pharmaceuticals, Inc. lowest stock price was $5.36 and its highest was $36.26 in the past 12 months.
What is Olema Pharmaceuticals, Inc.’s market cap?
Olema Pharmaceuticals, Inc.’s market cap is $935.35M.
When is Olema Pharmaceuticals, Inc.’s upcoming earnings report date?
Olema Pharmaceuticals, Inc.’s upcoming earnings report date is Nov 10, 2026 which is in 77 days.
How were Olema Pharmaceuticals, Inc.’s earnings last quarter?
Olema Pharmaceuticals, Inc. released its earnings results on Aug 10, 2026. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.551 by -$0.059.
Is Olema Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Olema Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Olema Pharmaceuticals, Inc. pay dividends?
Olema Pharmaceuticals, Inc. does not currently pay dividends.
What is Olema Pharmaceuticals, Inc.’s EPS estimate?
Olema Pharmaceuticals, Inc.’s EPS estimate is -0.64.
How many shares outstanding does Olema Pharmaceuticals, Inc. have?
Olema Pharmaceuticals, Inc. has 87,497,604 shares outstanding.
What happened to Olema Pharmaceuticals, Inc.’s price movement after its last earnings report?
Olema Pharmaceuticals, Inc. reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.551. Following the earnings report the stock price went down -12.647%.
Which hedge fund is a major shareholder of Olema Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in OLMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Olema Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.13 (225.85% Upside)
$38.13 (225.85% Upside)
Blogger Sentiment
Bullish
OLMA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $291.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.5%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
156.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
27.38%
Trailing 12-Months
Company Description
Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
OLMA Stock 12 Month Forecast
Average Price Target
$38.13
▲(225.85% Upside)
Technical Analysis
Meiragtx Holdings
―
Arvinas Holding Company
―
Gossamer Bio
―
Keros Therapeutics
―
Compass Therapeutics
―
Ownership Overview
10.18% Insiders
21.20% Mutual Funds
51.15% Other Institutional Investors
2.56% Public Companies and Individual Investors